Prostate Neoplasms Recruiting Phase 2 Trials for Enzalutamide (DB08899)

Also known as: Neoplasm, Prostate / Neoplasms, Prostate / Prostate Neoplasm

IndicationStatusPhase
DBCOND0031071 (Prostate Neoplasms)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03531827Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide TreatmentTreatment